Skip to content
PubMed This is a summary of 69 peer-reviewed journal articles Updated

Research & Literature

Explore the leading researchers and institutions driving advances in this area, and dive into the full body of literature that informs this resource.

Explore the Literature Visualize citation networks across 69 referenced papers

Top Authors

Fádi Fakhouri
Centre Hospitalier Universitaire Vaudois
Éric Rondeau
Sorbonne Université
Véronique Frémeaux‐Bacchi
Assistance Publique – Hôpitaux de Paris
François Provôt
Centre Hospitalier Universitaire de Lille
Yahsou Delmas
Centre Hospitalier Universitaire de Bordeaux
Neil Sheerin
Newcastle University
David Kavanagh
Royal Victoria Infirmary
Spero R. Cataland
The Ohio State University
Larry A. Greenbaum
Emory University
Gianluigi Ardissino
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

Top Institutions

Ranked by publications Top 10 institutions
08

Centre Hospitalier Universitaire de Bordeaux

Bordeaux, France

19 papers
09

Centre Hospitalier Universitaire de Lille

Lille, France

13 papers

References

References (69)
  1. 1

    Characterization of an autosomal dominant bleeding disorder caused by a thrombomodulin mutation.

    Dargaud Y, Scoazec JY, Wielders SJ, et al.

    Blood 2015; (125(9)):1497-501 doi:10.1182/blood-2014-10-604553.

    PMID: 25564403
  2. 2

    Primary postpartum haemorrhage in women with von Willebrand disease or carriership of haemophilia despite specialised care: a retrospective survey.

    Stoof SC, van Steenbergen HW, Zwagemaker A, et al.

    Haemophilia : the official journal of the World Federation of Hemophilia 2015; (21(4)):505-12 doi:10.1111/hae.12635.

    PMID: 25688733
  3. 3

    Case report: Benefits and challenges of long-term eculizumab in atypical hemolytic uremic syndrome.

    Cullinan N, Gorman KM, Riordan M, et al.

    Pediatrics 2015; (135(6)):e1506-9 doi:10.1542/peds.2014-3503.

    PMID: 25941307
  4. 4

    Thrombotic microangiopathy without renal involvement: two novel mutations in complement-regulator genes.

    Peyvandi F, Rossio R, Ferrari B, et al.

    Journal of thrombosis and haemostasis : JTH 2016; (14(2)):340-5 doi:10.1111/jth.13210.

    PMID: 26613809
  5. 5

    TNF Regulates Essential Alternative Complement Pathway Components and Impairs Activation of Protein C in Human Glomerular Endothelial Cells.

    Sartain SE, Turner NA, Moake JL

    Journal of immunology (Baltimore, Md. : 1950) 2016; (196(2)):832-45 doi:10.4049/jimmunol.1500960.

    PMID: 26673143
  6. 6

    Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.

    Fakhouri F, Hourmant M, Campistol JM, et al.

    American journal of kidney diseases : the official journal of the National Kidney Foundation 2016; (68(1)):84-93.

    PMID: 27012908
  7. 7

    Altered fibrinolysis in autosomal dominant thrombomodulin-associated coagulopathy.

    Burley K, Whyte CS, Westbury SK, et al.

    Blood 2016; (128(14)):1879-1883 doi:10.1182/blood-2016-05-716092.

    PMID: 27436851
  8. 8

    Present day management of inherited bleeding disorders in pregnancy.

    Kouides PA

    Expert review of hematology 2016; (9(10)):987-95 doi:10.1080/17474086.2016.1216312.

    PMID: 27459638
  9. 9

    Thrombomodulin enhances complement regulation through strong affinity interactions with factor H and C3b-Factor H complex.

    Heurich M, Preston RJ, O'Donnell VB, et al.

    Thrombosis research 2016; (145()):84-92.

    PMID: 27513882
  10. 10

    Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation.

    Fakhouri F, Fila M, Provôt F, et al.

    Clinical journal of the American Society of Nephrology : CJASN 2017; (12(1)):50-59 doi:10.2215/CJN.06440616.

    PMID: 27799617
  11. 11

    Nephrotic-Range Proteinuria and Peripheral Edema in a Child: Not Only Idiopathic Nephrotic Syndrome.

    Dolcemascolo V, Vivarelli M, Colucci M, et al.

    Case reports in nephrology and dialysis 2016; (6(3)):120-127 doi:10.1159/000449423.

    PMID: 27904864
  12. 12

    Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis.

    Laurence J, Haller H, Mannucci PM, et al.

    Clinical advances in hematology & oncology : H&O 2016; (14 Suppl 11(11)):2-15.

    PMID: 27930620
  13. 13

    Adjustment of Eculizumab Dosage Pattern in Patients with Atypical Hemolytic Uremic Syndrome with Suboptimal Response to Standard Treatment Pattern.

    García Monteavaro C, Peralta Roselló C, Quiroga B, et al.

    Case reports in nephrology 2016; (2016()):7471082 doi:10.1155/2016/7471082.

    PMID: 28025630
  14. 14

    Whole exome sequencing identifies a mutation in thrombomodulin as the genetic cause of a suspected platelet disorder in a family with normal platelet function.

    Maclachlan A, Dolan G, Grimley C, et al.

    Platelets 2017; (28(6)):611-613 doi:10.1080/09537104.2017.1283011.

    PMID: 28267383
  15. 15

    Atypical Hemolytic Uremic Syndrome: A Brief Review.

    Zhang K, Lu Y, Harley KT, Tran MH

    Hematology reports 2017; (9(2)):7053 doi:10.4081/hr.2017.7053.

    PMID: 28626544
  16. 16

    Lys 42/43/44 and Arg 12 of thrombin-activable fibrinolysis inhibitor comprise a thrombomodulin exosite essential for its antifibrinolytic potential.

    Wu C, Stafford AR, Fredenburgh JC, et al.

    Thrombosis and haemostasis 2017; (117(8)):1509-1517 doi:10.1160/TH17-01-0054.

    PMID: 28640323
  17. 17

    Routine use of clinical exome-based next-generation sequencing for evaluation of patients with thrombotic microangiopathies.

    Gaut JP, Jain S, Pfeifer JD, et al.

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2017; (30(12)):1739-1747 doi:10.1038/modpathol.2017.90.

    PMID: 28752844
  18. 18

    Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand.

    Fox LC, Cohney SJ, Kausman JY, et al.

    Nephrology (Carlton, Vic.) 2018; (23(6)):507-517 doi:10.1111/nep.13234.

    PMID: 29419916
  19. 19

    Brain microvascular endothelial cells exhibit lower activation of the alternative complement pathway than glomerular microvascular endothelial cells.

    Sartain SE, Turner NA, Moake JL

    The Journal of biological chemistry 2018; (293(19)):7195-7208 doi:10.1074/jbc.RA118.002639.

    PMID: 29555686
  20. 20

    Extra-Renal manifestations of atypical hemolytic uremic syndrome in children.

    Fidan K, Göknar N, Gülhan B, et al.

    Pediatric nephrology (Berlin, Germany) 2018; (33(8)):1395-1403 doi:10.1007/s00467-018-3933-3.

    PMID: 29610995
  21. 21

    Combined study of ADAMTS13 and complement genes in the diagnosis of thrombotic microangiopathies using next-generation sequencing.

    Fidalgo T, Martinho P, Pinto CS, et al.

    Research and practice in thrombosis and haemostasis 2017; (1(1)):69-80 doi:10.1002/rth2.12016.

    PMID: 30046676
  22. 22

    Genetic Analysis of 400 Patients Refines Understanding and Implicates a New Gene in Atypical Hemolytic Uremic Syndrome.

    Bu F, Zhang Y, Wang K, et al.

    Journal of the American Society of Nephrology : JASN 2018; (29(12)):2809-2819 doi:10.1681/ASN.2018070759.

    PMID: 30377230
  23. 23

    Impact of hypertensive emergency and rare complement variants on the presentation and outcome of atypical hemolytic uremic syndrome.

    El Karoui K, Boudhabhay I, Petitprez F, et al.

    Haematologica 2019; (104(12)):2501-2511 doi:10.3324/haematol.2019.216903.

    PMID: 30890598
  24. 24

    Updated Australian consensus statement on management of inherited bleeding disorders in pregnancy.

    Dunkley S, Curtin JA, Marren AJ, et al.

    The Medical journal of Australia 2019; (210(7)):326-332 doi:10.5694/mja2.50123.

    PMID: 30924538
  25. 25

    Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study.

    Menne J, Delmas Y, Fakhouri F, et al.

    BMC nephrology 2019; (20(1)):125 doi:10.1186/s12882-019-1314-1.

    PMID: 30971227
  26. 26

    Atypical Hemolytic Uremic Syndrome Presenting as Acute Heart Failure-A Rare Presentation: Diagnosis Supported by Skin Biopsy.

    Kichloo A, Chugh SS, Gupta S, et al.

    Journal of investigative medicine high impact case reports 2019; (7()):2324709619842905 doi:10.1177/2324709619842905.

    PMID: 31010328
  27. 27

    Deleterious Impact of a Novel CFH Splice Site Variant in Atypical Hemolytic Uremic Syndrome.

    Schönauer R, Seidel A, Grohmann M, et al.

    Frontiers in genetics 2019; (10()):465 doi:10.3389/fgene.2019.00465.

    PMID: 31156713
  28. 28

    Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome.

    Lee H, Kang E, Kang HG, et al.

    The Korean journal of internal medicine 2020; (35(1)):25-40 doi:10.3904/kjim.2019.388.

    PMID: 31935318
  29. 29

    Atypical haemolytic uraemic syndrome: a case report of a rare cause of reversible cardiomyopathy.

    Campbell CM, Cassol C, Cataland SR, Kahwash R

    European heart journal. Case reports 2020; (4(2)):1-6 doi:10.1093/ehjcr/ytaa050.

    PMID: 32352052
  30. 30

    A case of thrombomodulin mutation causing defective thrombin binding with absence of protein C and TAFI activation.

    Okada M, Tominaga N, Honda G, et al.

    Blood advances 2020; (4(12)):2631-2639 doi:10.1182/bloodadvances.2019001155.

    PMID: 32556284
  31. 31

    A new pedigree with thrombomodulin-associated coagulopathy in which delayed fibrinolysis is partially attenuated by co-inherited TAFI deficiency.

    Westbury SK, Whyte CS, Stephens J, et al.

    Journal of thrombosis and haemostasis : JTH 2020; (18(9)):2209-2214 doi:10.1111/jth.14990.

    PMID: 32634856
  32. 32

    The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab.

    Tanaka K, Adams B, Aris AM, et al.

    Pediatric nephrology (Berlin, Germany) 2021; (36(4)):889-898 doi:10.1007/s00467-020-04774-2.

    PMID: 33048203
  33. 33

    Characterisation of a novel thrombomodulin c.1487delC,p.(Pro496Argfs*10) variant and evaluation of therapeutic strategies to manage the rare bleeding phenotype.

    Morrow GB, Beavis J, Harper S, et al.

    Thrombosis research 2021; (197()):100-108 doi:10.1016/j.thromres.2020.11.002.

    PMID: 33190022
  34. 34

    Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study.

    Fakhouri F, Fila M, Hummel A, et al.

    Blood 2021; (137(18)):2438-2449 doi:10.1182/blood.2020009280.

    PMID: 33270832
  35. 35

    Haemoglobinuria for the early identification of aHUS relapse: data from the ItalKId-HUS Network.

    Brambilla M, Ardissino G, Paglialonga F, et al.

    Journal of nephrology 2022; (35(1)):279-284 doi:10.1007/s40620-021-00965-8.

    PMID: 33459950
  36. 36

    Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics.

    Fakhouri F, Frémeaux-Bacchi V

    Nature reviews. Nephrology 2021; (17(8)):543-553 doi:10.1038/s41581-021-00424-4.

    PMID: 33953366
  37. 37

    Hematologic Findings in Pregnancy: A Guide for the Internist.

    Patel P, Balanchivadze N

    Cureus 2021; (13(5)):e15149 doi:10.7759/cureus.15149.

    PMID: 34164247
  38. 38

    Thrombomodulin (THBD) gene variants and thrombotic risk in a population-based cohort study.

    Manderstedt E, Halldén C, Lind-Halldén C, et al.

    Journal of thrombosis and haemostasis : JTH 2022; (20(4)):929-935 doi:10.1111/jth.15630.

    PMID: 34970867
  39. 39

    [CME: Diagnostic Approach and Management of Thrombotic Microangiopathy].

    Sutter T, Fehr T, Venzin R

    Praxis 2022; (111(14)):771-777 doi:10.1024/1661-8157/a003927.

    PMID: 36285415
  40. 40

    Visualization of Domain- and Concentration-Dependent Impact of Thrombomodulin on Differential Regulation of Coagulation and Fibrinolysis.

    Mochizuki L, Sano H, Honkura N, et al.

    Thrombosis and haemostasis 2023; (123(1)):16-26 doi:10.1055/s-0042-1757407.

    PMID: 36307100
  41. 41

    Atypical hemolytic uremic syndrome: Consensus of diagnosis and treatment in Taiwan.

    Tseng MH, Lin SH, Tsai JD, et al.

    Journal of the Formosan Medical Association = Taiwan yi zhi 2023; (122(5)):366-375 doi:10.1016/j.jfma.2022.10.006.

    PMID: 36323601
  42. 42

    Von Willebrand Disease, Hemophilia, and Other Inherited Bleeding Disorders in Pregnancy.

    Pacheco LD, Saade GR, James AH

    Obstetrics and gynecology 2023; (141(3)):493-504 doi:10.1097/AOG.0000000000005083.

    PMID: 36800851
  43. 43

    Atypical Hemolytic Uremic Syndrome in a Pregnant Patient with a Thrombomodulin Gene Variant Treated with Plasma Exchange and Eculizumab.

    Kannan L

    The American journal of case reports 2023; (24()):e938896 doi:10.12659/AJCR.938896.

    PMID: 37120715
  44. 44

    Rare inherited coagulation and fibrinolytic defects that challenge diagnostic laboratories.

    Mathews N, Tasneem S, Hayward CPM

    International journal of laboratory hematology 2023; (45 Suppl 2()):30-43 doi:10.1111/ijlh.14084.

    PMID: 37211424
  45. 45

    Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort study.

    Brocklebank V, Walsh PR, Smith-Jackson K, et al.

    Blood 2023; (142(16)):1371-1386 doi:10.1182/blood.2022018833.

    PMID: 37369098
  46. 46

    Genotypic analysis of a large cohort of patients with suspected atypical hemolytic uremic syndrome.

    Connaughton DM, Bhai P, Isenring P, et al.

    Journal of molecular medicine (Berlin, Germany) 2023; (101(8)):1029-1040 doi:10.1007/s00109-023-02341-4.

    PMID: 37466676
  47. 47

    Surgery in rare bleeding disorders: the prospective MARACHI study.

    Rousseau F, Guillet B, Mura T, et al.

    Research and practice in thrombosis and haemostasis 2023; (7(7)):102199 doi:10.1016/j.rpth.2023.102199.

    PMID: 37867585
  48. 48

    Management of pregnant women who have bleeding disorders.

    James AH, Pacheco LD, Konkle BA

    Hematology. American Society of Hematology. Education Program 2023; (2023(1)):229-236 doi:10.1182/hematology.2023000475.

    PMID: 38066866
  49. 49

    Medical consult: aHUS, TTP? How to distinguish and what to do.

    Story CM, Gerber GF, Chaturvedi S

    Hematology. American Society of Hematology. Education Program 2023; (2023(1)):745-753 doi:10.1182/hematology.2023000501.

    PMID: 38066937
  50. 50

    Recommendations for the individualised management of atypical hemolytic uremic syndrome in adults.

    Ávila A, Cao M, Espinosa M, et al.

    Frontiers in medicine 2023; (10()):1264310 doi:10.3389/fmed.2023.1264310.

    PMID: 38105887
  51. 51

    Thrombomodulin: a multifunctional receptor modulating the endothelial quiescence.

    Giri H, Biswas I, Rezaie AR

    Journal of thrombosis and haemostasis : JTH 2024; (22(4)):905-914 doi:10.1016/j.jtha.2024.01.006.

    PMID: 38266676
  52. 52

    How to investigate mild to moderate bleeding disorders and bleeding disorder of unknown cause.

    Casini A, Gebhart J

    International journal of laboratory hematology 2024; (46 Suppl 1()):27-33 doi:10.1111/ijlh.14266.

    PMID: 38454298
  53. 53

    A Rare Case of Atypical Hemolytic Uremic Syndrome Presenting as Chronic Interstitial Nephritis.

    Muralidharan S, Mathew GG, Alwan A, Jayaprakash V

    Cureus 2024; (16(7)):e65274 doi:10.7759/cureus.65274.

    PMID: 39184759
  54. 54

    Thrombomodulin: A key regulator of intravascular blood coagulation, fibrinolysis, and inflammation, and a treatment for disseminated intravascular coagulation.

    Suzuki K

    Proceedings of the Japan Academy. Series B, Physical and biological sciences 2025; (101(2)):75-97 doi:10.2183/pjab.101.006.

    PMID: 39694492
  55. 55

    Functional assessment of genetic variants in thrombomodulin detected in patients with bleeding and thrombosis.

    Van Laer C, Lavend'homme R, Baert S, et al.

    Blood 2025; (145(17)):1929-1942 doi:10.1182/blood.2024026454.

    PMID: 39841007
  56. 56

    Atypical Hemolytic Uremic Syndrome Triggered by COVID-19 Infection in a Pediatric Patient With CD46 Mutation.

    Lorestani P, Maleki Dana P, Tohidi MR

    Clinical case reports 2025; (13(3)):e70308 doi:10.1002/ccr3.70308.

    PMID: 40093928
  57. 57

    Thrombotic Microangiopathies.

    Hanna R, Gibney R, Boysen-Osborn M

    Emergency medicine clinics of North America 2025; (43(3)):407-420 doi:10.1016/j.emc.2025.03.008.

    PMID: 40610058
  58. 58

    Laboratory diagnosis of congenital and acquired coagulopathies, including challenging-to-diagnose rare bleeding disorders.

    Al Dawood R, Hayward CPM

    Pathology 2025; (57(6)):687-695 doi:10.1016/j.pathol.2025.06.004.

    PMID: 40796410
  59. 59

    Society for Perioperative Assessment and Quality Improvement: a narrative review of best practices for perioperative management of patients with bleeding disorders.

    Khambaty M, Connors JM, Grawe ES, et al.

    British journal of anaesthesia 2025; (135(5)):1269-1278 doi:10.1016/j.bja.2025.07.090.

    PMID: 41027819
  60. 60

    [Ultra-early administration of eculizumab in a child with atypical hemolytic uremic syndrome: a case report].

    Guo DD, Xiao YX, Wang WR, et al.

    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 2025; (27(11)):1408-1413 doi:10.7499/j.issn.1008-8830.2503084.

    PMID: 41250542
  61. 61

    Eculizumab withdrawal and monitoring in atypical haemolytic uraemic syndrome (SETS aHUS): a multicentre, open label, prospective, single arm trial.

    Bryant A, Lecouturier J, Orozco-Leal G, et al.

    The Lancet regional health. Europe 2025; (56()):101392 doi:10.1016/j.lanepe.2025.101392.

    PMID: 41550273
  62. 62

    Thrombin Generation Measurement: A Novel Diagnostic and Prognostic Approach for Identifying Early-Stage Disseminated Intravascular Coagulation in Individuals with Sepsis.

    Turkal R, Çevlik T, Tekin AF, et al.

    Journal of intensive care medicine 2026; (41(9)):904-915 doi:10.1177/08850666261423151.

    PMID: 41707669
  63. 63

    Beyond Vaccination: Persistent Meningococcal Risk in Anti-C5-Treated aHUS-Case Report and Review of Literature.

    Matarese S, Brisca G, Moscatelli A, et al.

    Journal of clinical medicine 2026; (15(8)) doi:10.3390/jcm15083048.

    PMID: 42074848
  64. 64

    Bleeding Risk Assessment and Management Strategies for Elective Surgery and Invasive Procedures: A Systematic Review.

    Alsagga H, Bassiony MI, Eladani OMB, et al.

    Cureus 2026; (18(5)):e108286 doi:10.7759/cureus.108286.

    PMID: 42255763
  65. 65

    A case report of atypical hemolytic uremic syndrome with a CFH mutation complicated by recurrent posterior reversible encephalopathy syndrome.

    Maruyama R, Takeuchi D, Momose M, et al.

    Medicine 2026; (105(27)):e49593 doi:10.1097/MD.0000000000049593.

    PMID: 42410819
  66. 66

    Thrombomodulin Gly430Ser mutation attenuates the affinity with thrombin and contributes to thrombosis development.

    Chen N, Lai Z, Yuan J, et al.

    Journal of thrombosis and thrombolysis 2026; doi:10.1007/s11239-026-03379-0.

    PMID: 42521976
  67. 67

    Atypical hemolytic uremic syndrome in kidney transplantation.

    Ponticelli C, Moroni G

    Journal of nephrology 2026; (39(7)):1334-1341 doi:10.1093/joneph/aajag096.

    PMID: 42742155
  68. 68

    Atypical hemolytic uremic syndrome: pathophysiology, clinical presentation, and treatment strategies.

    Song JY

    Childhood kidney diseases 2025; (29(2)):52-59 doi:10.3339/ckd.25.017.

    PMID: 42779682
  69. 69

    Case Report: Atypical hemolytic uremic syndrome triggered by Rhinovirus/Enterovirus infection with cutaneous thrombotic microangiopathy requiring surgical management.

    Shen J, Cai K, Kang W, et al.

    Frontiers in pediatrics 2026; (14()):1973640 doi:10.3389/fped.2026.1973640.

    PMID: 42973488